原发性硬化性胆管炎伴IgG4升高1例报告

陈庆灵; 仲瑞; 方伊娜; 张晓雪; 冯丽娜; 杨倩倩; 温晓玉; 金清龙

doi:10.3969/j.issn.1001-5256.2019.09.035

原发性硬化性胆管炎伴IgG4升高1例报告

DOI: 10.3969/j.issn.1001-5256.2019.09.035

1. 吉林大学第一医院肝胆胰内科
2. 吉林大学第一医院神经内科

详细信息

中图分类号: R575.7
计量
- 文章访问数: 1064
- HTML全文浏览量: 8
- PDF下载量: 309
- 被引次数: 0
出版历程
- 出版日期: 2019-09-20

Primary sclerosing cholangitis with elevated IgG4 levels: A case report

Department of Hepatology, The First Hospital of Jilin University

摘要

摘要: <正>原发性硬化性胆管炎（PSC）是一种慢性进展性胆汁淤积性肝病,其典型的病理改变为胆管炎症及胆管周围同心圆性洋葱皮样纤维化、肝内外胆管破坏导致多灶性胆管狭窄,最终可发展为肝硬化、肝衰竭甚至死亡,此病虽然少见,但其发病率逐年上升[1]。IgG 4相关性硬化性胆管炎（IgG 4-related sclerosing cholangitis,IgG 4-SC）的概念是由Bjornsson等[2]于2007年首先提出,是指一类以胆管周围IgG 4阳性浆细胞浸润及纤维化
- 胆管炎,硬化性 /
- 免疫球蛋白G /
- 诊断 /
- 肝移植
- cholangitis, sclerosing /
- immunoglobulin G /
- diagnosis /
- liver transplantation

HTML全文

参考文献(22)

[1] RIZVI S, EATON J E, GORES G J. Primary sclerosing cholangitis as a premalignant biliary tract disease:Surveillance and management[J]. Clin Gastroenterol Hepatol, 2015, 13 (12) :2152-2165.

[2] BJOMSSON E, CHARI ST, SMYRK TC, et al. Immunoglobulin G4 associated cholangitis:Description of an emerging clinical entity based on review of the literature[J]. Hepatology, 2007, 45 (6) :1547-1554.

[3] ZEN Y, HARADA K, SASAKI M, et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis:Do they belong to a spectrum of sclerosing pancreatitis?[J]. Am J Surg Pathol, 2004, 28 (9) :1193-1203.

[4] NI QQ, WU HM, HUA J. An excerpt of JSGE guidelines for primary sclerosing cholangitis (2017) [J]. J Clin Hepatol, 2018, 34 (9) :1873-1876. (in Chinese) 倪茜茜, 吴惠敏, 华静.《2017年日本胃肠病学会原发性硬化性胆管炎临床指南》摘译[J].临床肝胆病杂志, 2018, 34 (9) :1873-1876.

[5] MENDES FD, JORGENSEN R, KEACH J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis[J]. Am J Gastroenterol, 2006, 101 (9) :2070-2075.

[6] JIANG X, KARLSEN TH. Genetics of primary sclerosing cholangitis and pathophysiological implications[J]. Nat Rev Gastroenterol Hepatol, 2017, 14 (5) :279-295.

[7] JI SG, JURAN BD, MUCHA S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease[J]. Nat Genet, 2017, 49 (2) :269-273.

[8] FOLSERAAS T, MELUM E, RAUSCH P, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci[J]. J Hepatol, 2012, 57 (2) :366-375.

[9] HENRIKSEN E, VIKEN MK, WITTIG M, et al. HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry[J]. HLA, 2017, 90 (4) :228-233.

[10] BEMTSEN NL, KLINGENBERG O, JURAN BD, et al. Association between HLA haplotypes and increased serum levels of IgG4 in patients with primary sclerosing cholangitis[J]. Gastroenterology, 2015, 148 (5) :924-927.

[11] HOV JR, BOBERG KM, TARALDSRUD E, et al. Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis[J]. Liver Int, 2017, 37 (3) :458-465.

[12] TANAKA A, TAZUMA S, NAKAZAWA T, et al. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan[J]. J Hepatobiliary Pancreat Sci, 2017, 24 (4) :217-225.

[13] AABAKKEN L, KARLSEN T H, ALBERT J, et al. Role of endoscopy in primary sclerosing cholangitis:European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline[J].Endoscopy, 2017, 49 (6) :588-608.

[14] ZHU JY, QI LG, HAN Y. Differential diagnosis and research development of primary sclerosing cholangitis and immunoglobulin G4-associated cholangitis[J]. Chin J Hepatol, 2013, 21 (2) :154-157. (in Chinese) 朱疆依, 齐林篙, 韩英.原发性硬化性胆管炎和IgG4相关性胆管炎的鉴别及诊治进展[J].中华肝脏病杂志, 2013, 21 (2) :154-157.

[15] DYSON JK, BEUERS U, JONES D, et al. Primary sclerosing cholangitis[J]. Lancet, 2018, 391 (10139) :2547-2559.

[16] ZHANG LL, FAN YJ, TAN B, et al. Recognition of the clinical application and biological mechanism of ursodexycholic acid in liver diseases[J]. Chin J Clin Pharmacol Ther, 2017, 22 (2) :233-240. (in Chinese) 张林林, 樊玉娟, 谭波, 等.熊脱氧胆酸在慢性肝病中应用及机制的再认识[J].中国临床药理学与治疗学, 2017, 22 (2) :233-240.

[17] HALILBASIC E, FUCHS C, HOFER H, et al. Therapy of primary sclerosing cholangitis—today and tomorrow[J]. Dig Dis, 2015, 33 (Suppl 2) :149-163.

[18] GOLDBERG DS. Liver transplant in patients with primary sclerosing cholangitis[J]. Gastroenterol Hepatol (N Y) , 2016, 12 (2) :127-129.

[19] OSEINI AM, CHAITEERAKIJ R, SHIRE AM, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma[J]. Hepatology, 2011, 54 (3) :940-948.

[20] OKAZAKI K, UCHIDA K, KOYABU M, et al. IgG4 cholangiopathy:Current concept, diagnosis, and pathogenesis[J]. J Hepatol, 2014, 61 (3) :690-695.

[21] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of cholestatic liver diseases[J]. J Hepatol, 2009, 51 (2) :237-267.

[22] BERGQUIST A, MONTGOMERY SM, BAHMANYAR S, et al.Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2008, 6 (8) :939-943.

施引文献

资源附件(0)

访问统计